The Primary Sjogren’s Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Primary Sjogren’s Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Primary Sjogren’s Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Primary Sjogren’s Syndrome and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Primary Sjogren’s Syndrome by 12 companies/universities/institutes. The top development phase for Primary Sjogren’s Syndrome is phase ii with eight drugs in that stage. The Primary Sjogren’s Syndrome pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Primary Sjogren’s Syndrome pipeline products market are: Bristol-Myers Squibb, Argenx and Novartis.
The key targets in the Primary Sjogren’s Syndrome pipeline products market include IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN), CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG), and Bone Morphogenetic Protein 6 (VG 1 Related Protein or BMP6).
The key mechanisms of action in the Primary Sjogren’s Syndrome pipeline product include IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN) Antagonist with two drugs in Phase II. The Primary Sjogren’s Syndrome pipeline products include four routes of administration with the top ROA being Intravenous and six key molecule types in the Primary Sjogren’s Syndrome pipeline products market including Monoclonal Antibody, and Small Molecule.
Primary Sjogren’s Syndrome overview
Primary Sjogren’s Syndrome is a common chronic autoimmune disorder that affects the lacrimal and salivary glands, and some may develop extra glandular involvement of joints, GI tract, lungs, skin, CNS, and kidneys. Dry eyes and dryness of mouth are characteristic features of this condition. Joint pain, skin rashes, and dry cough are some other symptoms. Eye drops treat dry eyes which are composed of corticosteroids. Hydration to treat dry mouth and preventive care to treat complications associated.
For a complete picture of Primary Sjogren’s Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
